English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

American Home Products, the maker of Pondim (fenfluramine) and Redux (dexfenfluramine), recently agreed to pay as much as $3.75 billion to people who took the diet drug cocktail called fen-phen or Redux, a settlement that attorneys called the largest ever involving a US pharmaceutical firm (fen-phen was a combination of fenfluramine and phentermine). The nationwide, class-action settlement is open to all who took Redux or Pondim, regardless of whether they have filed suit or not.The settlement has yet to be approved by a federal judge, who must certify the suit. A similar attempt to settle product liability litigation by Interneuron Pharmaceuticals, Inc, met a stumbling block last September when the US District Court for the Eastern District of Pennsylvania rejected a proposed agreement between the company and the plaintiffs’ management committee on the grounds that the proposed settlement did not meet the requirements for limited fund class actions. Interneuron, which is based in Lexington, Mass, licensed dexfenfluramine from the closely held French drugmaker Laboratoires Servier SA and manufactured it for American Home Products Corp.The American Home Products settlement will fund the following:

Diet Drug Maker Agrees to $3.75 Billion Settlement